PipelineReview.com1d
Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
BAGSVAERD, Denmark I January 17, 2025 I Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is ...
PipelineReview.com1d
FDA approves Lumakras® (sotorasib) in combination with Vectibix® (panitumumab) for chemorefractory KRAS G12C-mutated metastatic colorectal cancer
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC ...
PipelineReview.com3d
FDA approves Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, expanding its use to the second major type of inflammatory bowel disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year ...
PipelineReview.com6d
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
TEL AVIV, Israel I January 13, 2025 I Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) ...
PipelineReview.com5d
Pheno Therapeutics Granted Clinical Trial Authorisation for Lead Multiple Sclerosis Therapeutic Candidate PTD802
EDINBURGH, UK I January 14, 2025 I Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule ...
PipelineReview.com3d
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company
CAMBRIDGE, MA, USA I January 15, 2025 I Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in B Cell Medicines (BCMs), today announced the closing of ...
PipelineReview.com3d
Chromatin Bioscience’s synthetic promoter supports EsoBiotec’s ESO-T01 CAR-T therapy as it enters the clinic
EDINBURGH, UK I January 15, 2025 I Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced ...
PipelineReview.com4d
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
WHIPPANY, NJ, USA I January 14, 2025 I On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in ...
PipelineReview.com5d
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
ROCKVILLE, MD, USA I January 14, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership ...
PipelineReview.com5d
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
NORTH CHICAGO, IL and ROCKVILLE, MD, USA I January 13, 2025 I AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ...